News

18

Mar
2015

CELLIPSE bid selected by EU Lead Factory

CELLIPSE was awarded an exclusive High Thoughput Screening research to screen the EU Lead Factory joint compound library on an undisclosed innovative target, by the Screening Selection Committees of EU Lead Factory (ELF) on January 19 2015.

The kickoff meeting was held in mid February and the effort, led by Dr Renaud Prudent from CELLIPSE and Dr Helma Rutjes from ELF’s partner Pivot Park Screening Centre, should yield its first results within 9 months.

“We are delighted to be selected for the ELF screening initiative as it gives CELLIPSE the promise of new  high quality hits from ELF’s curent >350,000-compound strong chemical library to develop potential first-in-class therapies against our target. Also, these chemical assets will be highly complementary to the ones that we are currently developing in house for leukemia” stated Dr Prudent, CELLIPSE’s Chief Operating Officer. “This gives us a fantastic opportunity, if we are successful, to partner with leading European pharmaceutical companies such as  Bayer, Sanofi, Janssen, Merck, AstraZeneca, Lundbeck or UCB who are providing their chemical assets to the ELF initiative” added Fabrice Paublant CELLIPSE’s CEO.

About EU Lead Factory (ELF): ELF is a unique public-private partnership that promotes  new discoveries via open innovation and crowd sourcing. It is designed to provide best-in-class resources and funding-in-kind, to academics or SMEs who are working on promising biology targets or chemistry scaffolds. It is financed jointly by the Innovative Medicine Initiative from FP7 EU Grants Programme and EFPIA companies in kind contribution. To know more about EU Lead Factory, please click here.

To read the Press Release click on PR 2015-01 ENG CELLIPSE EU Lead Factory.